Publications Complete Remission of Widely Metastatic Human Epidermal Growth Factor Receptor 2-Amplified Pancreatic Adenocarcinoma After Precision Immune and Targeted Therapy with Description of Sequencing and Organoid Correlates. JCO Precis. Oncol. 2023Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing. NPJ Precis. Oncol. 2023Case report: ex vivo tumor organoid drug testing identifies therapeutic options for stage IV ovarian carcinoma. Front. Oncol. 2024Patient derived organoids to model rare prostate cancer phenotypes. Nature Communications 2018Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer. Clinical Cancer research 2018Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy. Clinical Cancer Research 2020Functional drug screening of organoids from ovarian cancer patients demonstrates clinical and genomic concordance and identifies novel therapeutic vulnerabilities. Volume 81, Issue 13_Supplement 2021, Cancer ResearchTumor organoid based drug sensitivity testing in ovarian cancer identifies exceptional responders to targeted therapies. Volume 83, Issue 7_Supplement 2023, Cancer Research case reports: the real-world impact of the PARIS® Test Ovarian cancer patient achieves meaningful recovery through PARIS-guided therapyPancreatic cancer patient achieves complete remission with HER2-directed treatment identified by PARIS Get Started
